When Gilead Sciences (NASDAQ: GILD) reports its fourth-quarter and 2016 full-year results on Feb. 7, investors will examine its financial performance in detail. They’ll look for clues that might predict what will happen next for the big biotech. What’s the single most important number for Gilead Sciences? I’d say its cash flow. Here’s why.
Image source: Getty Images
The old saying that “cash is king” is true in most cases. However, I think that cash flow is an even greater king.